FOLH1 and posterior cortical atrophy: 18F-flotufolastat was recently approved by the U.S. Food and Drug Administration for diagnostic PET imaging of PSMA-positive lesions in men with PCa (5) and was included in the most recent guideline updates from National Comprehensive Cancer Network and the American Society of Clinical Oncology (1,6).